Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) reported Operating Margin of 7382.41% for Q1 2026, down 667875.0% on a YoY basis from N/an in Q1 2025, and down 14228.3% quarter-over-quarter from 51.52% in Q4 2025.
Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported Operating Margin for 9 years, with the latest figure at 7382.41% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 667875.0% year-over-year to 7382.41%; the trailing twelve-month figure through Mar 2026 stood at 381.67% (up 58389.0% YoY), and the FY2025 full-year result was 340.38%, up 25458.0% from the prior year.
- Operating Margin for Q1 2026 stood at 7382.41%, down from 51.52% in the prior quarter.
- The five-year high for Operating Margin was 51.52% in Q4 2025, with the low at 7382.41% in Q1 2026.
- Historically, Operating Margin has averaged 1310.08% across 5 years, with a median of 709.4% in 2022.
- Annual changes were most pronounced in 2025 — Operating Margin jumped 182723 bps — and 2026, when it plunged 667875 bps.
- Bicycle Therapeutics' Operating Margin stood at 383.46% in 2022, then slumped by 165 bps to 1017.35% in 2023, then plunged by 79 bps to 1824.78% in 2024, then surged by 97 bps to 51.52% in 2025, then tumbled by 14228 bps to 7382.41% in 2026.
- The last three Operating Margin figures came in at 7382.41% (Q1 2026), 51.52% (Q4 2025), and 558.64% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -7,382.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,382.41% |
| Dec 31, 2025 | -51.52% |
| Sep 30, 2025 | -558.64% |
| Jun 30, 2025 | -2,965.82% |
| Mar 31, 2025 | -703.66% |
| Dec 31, 2024 | -1,824.78% |
| Sep 30, 2024 | -2,385.87% |
| Jun 30, 2024 | -498.31% |
| Mar 31, 2024 | -304.96% |
| Dec 31, 2023 | -1,017.35% |
| Sep 30, 2023 | -949.12% |
| Jun 30, 2023 | -378.27% |
| Mar 31, 2023 | -853.82% |
| Dec 31, 2022 | -383.46% |
| Sep 30, 2022 | -978.91% |
| Jun 30, 2022 | -325.00% |
| Mar 31, 2022 | -709.40% |
| Dec 31, 2021 | -1,126.50% |
| Sep 30, 2021 | -329.89% |
| Jun 30, 2021 | -967.90% |